ERLIN2: A promising drug target and biomarker for the treatment of lipid raft-associated diseases

Target Name: ERLIN2

NCBI ID: G11160

ERLIN2

ERLIN2: A promising drug target and biomarker for the treatment of lipid raft-associated diseases

Abstract:

Lipid raft-associated diseases, such as nonalcoholic steatohepatitis (NASH), biliary tract cancer, and cardiovascular diseases, have a significant impact on human health and wellbeing. ERLIN2, a novel lipid raft-associated protein, has been identified as a potential drug target and biomarker for the treatment of these diseases. This review will discuss the current understanding of ERLIN2, its potential as a drug target, and its potential as a biomarker for the diagnosis and monitoring of these diseases.

Introduction:

Nonalcoholic steatohepatitis (NASH), biliary tract cancer, and cardiovascular diseases are major health concerns worldwide, affecting millions of individuals. The underlying causes of these diseases are not well understood, but they are associated with the presence of lipid rafts in the liver and other tissues. Lipid rafts are self- Assembling structures that mediate the transport of lipids and other molecules across cell membranes and are involved in various cellular processes, including inflammation, metabolism, and signaling. The presence of lipid rafts is also associated with an increased risk of developing diseases such as NASH, biliary tract cancer, and cardiovascular diseases.

In recent years, efforts have been made to identify potential drug targets and biomarkers for the treatment of these diseases. One of the promising candidates is ERLIN2, a novel lipid raft-associated protein (LRP) that has been identified in various organisms, including humans. ERLIN2 has been shown to play a crucial role in the formation and maintenance of lipid rafts and has been linked to the development and progression of various diseases.

Current understanding of ERLIN2:

The present understanding of ERLIN2 is based on several studies that have shown its involvement in the formation and maintenance of lipid rafts and its potential as a drug target and biomarker for various diseases.

First, ERLIN2 has been shown to be a key regulator of lipid raft formation in various organisms, including humans. Several studies have shown that ERLIN2 plays a crucial role in the regulation of lipid raft size, stability, and dynamics. For example, ERLIN2 has been shown to promote the formation of large and stable lipid rafts in cell culture and has been shown to inhibit the formation of smaller and more dynamic rafts. Additionally, ERLIN2 has been shown to regulate the level of phosphorylation on the target protein, known as PIP3, which is involved in the formation and stability of lipid rafts.

Second, ERLIN2 has been shown to be involved in the development and progression of various diseases, including NASH, biliary tract cancer, and cardiovascular diseases. Several studies have shown that individuals with genetic variations in ERLIN2 are at an increased risk of developing these diseases. For example, one study has shown that individuals with a genetic variation in ERLIN2 are at an increased risk of developing NASH and biliary tract cancer. Additionally, another study has shown that individuals with a genetic variation in ERLIN2 are at an increased risk of developing cardiovascular diseases.

Potential as a drug target:

The potential of ERLIN2 as a drug target is based on its involvement in the formation and maintenance of lipid rafts and its association with various diseases. Several studies have shown that modulating ERLIN2 function could be a promising approach for the treatment of NASH, biliary tract cancer, and cardiovascular diseases.

One potential approach to modulate ERLIN2 function is through the inhibition of its activity. Several studies have shown that inhibitors of ERLIN2, such as{-

Protein Name: ER Lipid Raft Associated 2

Functions: Component of the ERLIN1/ERLIN2 complex which mediates the endoplasmic reticulum-associated degradation (ERAD) of inositol 1,4,5-trisphosphate receptors (IP3Rs) such as ITPR1 (PubMed:19240031, PubMed:17502376). Promotes sterol-accelerated ERAD of HMGCR probably implicating an AMFR/gp78-containing ubiquitin ligase complex (PubMed:21343306). Involved in regulation of cellular cholesterol homeostasis by regulation the SREBP signaling pathway. May promote ER retention of the SCAP-SREBF complex (PubMed:24217618)

The "ERLIN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERLIN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets